1-3 of 3
Savvas Toumanidis
Close
Sort by
Journal Articles

Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies

Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Alexandra Gkougkoutsi, Constantinos Pamboukas, Elisavet Kaldara, Argirios Dalianis, Erasmia Psimenou, Savvas Toumanidis, Evangelos Terpos, Meletios A Dimopoulos, MD
Journal: Blood
Blood (2012) 120 (21): 1786.
https://doi.org/10.1182/blood.V120.21.1786.1786
Published: 2012
Journal Articles

A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.

Efstathios Kastritis, Maria Roussou, Magdalini Migkou, Konstantinos Pamboukas, Maria Gavriatopoulou, Dimitrios Gogos, Konstantinos Liapis, Eurydiki Michalis, Sosana Delimpasi, Erasmia Psimenou, Savvas Toumanidis, Sofocles A. Kontoyannis, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood
Blood (2009) 114 (22): 428.
https://doi.org/10.1182/blood.V114.22.428.428
Published: 2009
Journal Articles

Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.

Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Maria Roussou, MD, Savvas Toumanidis, MD, Constantinos Pamboukas, MD, Anna Tassidou, MD, Irini Xilouri, MD, Sossana Delimpassi, MD, Erasmia Psimenou, MD, Sofia Mellou, MD, Evangelos Terpos, MD, John Nanas, MD, Meletios Athanasios Dimopoulos, MD
Journal: Blood
Blood (2007) 110 (11): 191.
https://doi.org/10.1182/blood.V110.11.191.191
Published: 2007